| Name |
Fludarabine phosphate (JAN/USP);Fludara (TN) |
| Product |
|
| Generic |
FLUDARABINE (Fresenius Kabi USA), FLUDARABINE PHOSPHATE (Actavis Pharma), FLUDARABINE PHOSPHATE (Areva Pharmaceuticals), FLUDARABINE PHOSPHATE (Lannett Company), FLUDARABINE PHOSPHATE (Sagent Pharmaceuticals) |
| Formula |
C10H13FN5O7P |
| Exact mass |
365.0537 |
| Mol weight |
365.21 |
| Structure |
 |
| Simcomp |
|
| Class |
Antineoplastic DG02018 Antimetabolite DG01958 Nucleic acid derivative, antineoplastic DG01439 Arabinofuranosyl type antineoplastic |
| Remark |
Therapeutic category: 4229ATC code: L01BB05Chemical structure group: DG00685Product (DG00685): D01907<JP/US> |
| Efficacy |
Antineoplastic, Antimetabolite |
| Disease |
B-cell chronic lymphocytic leukemia [DS:H00005] |
| Comment |
Active form of prodrug: Fludarabine [DR:D07966] |
| Target |
RRM1 [HSA:6240] [KO:K10807]DNA polymeraseRNA polymerase |
| Pathway |
hsa00230 Purine metabolismhsa00240 Pyrimidine metabolism |
| Interaction |
|
| Structure map |
map07041 Antineoplastics - antimetabolic agentsmap07044 Antiviral agents |
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01B ANTIMETABOLITES L01BB Purine analogues L01BB05 Fludarabine D01907 Fludarabine phosphate (JAN/USP) <JP/US>USP drug classification [BR:br08302] Antineoplastics Antimetabolites Fludarabine D01907 Fludarabine phosphate (JAN/USP)Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 422 Antimetabolites 4229 Others D01907 Fludarabine phosphate (JAN/USP)Drug groups [BR:br08330] Antineoplastic DG02018 Antimetabolite DG01958 Nucleic acid derivative, antineoplastic DG01439 Arabinofuranosyl type antineoplastic DG00685 Fludarabine D01907 Fludarabine phosphateDrug classes [BR:br08332] Antineoplastic DG02018 Antimetabolite D01907 Fludarabine phosphateTarget-based classification of drugs [BR:br08310] Enzymes Oxidoreductases (EC1) Ribonucleoside-diphosphate reductase RRM1 D01907 Fludarabine phosphate (JAN/USP) <JP/US>Prodrugs [br08324.html] D01907Drug groups [BR:br08330] Antineoplastic DG02018 Antimetabolite DG01958 Nucleic acid derivative, antineoplastic DG01439 Arabinofuranosyl type antineoplastic DG00685 Fludarabine |
| Other DBs |
CAS: 75607-67-9PubChem: 7848969ChEBI: 63599LigandBox: D01907NIKKAJI: J535.382C |
| LinkDB |
|
| KCF data |
ATOM 24 1 C1y C 11.4800 -11.6200 2 C1y C 12.8800 -11.6200 3 C1y C 13.3126 -10.2885 4 O2x O 12.1800 -9.4656 5 C1y C 11.0474 -10.2885 6 O1a O 10.7800 -12.8324 7 O1a O 13.5800 -12.8324 8 N5x N 15.7375 -11.6885 9 C8y C 15.7375 -10.2885 10 N4y N 14.5251 -9.5885 11 C1b C 9.8349 -9.5885 12 O2b O 8.6225 -10.2885 13 C8y C 16.9499 -12.3885 14 N5x N 18.1624 -11.6885 15 C8y C 18.1624 -10.2885 16 C8y C 16.9499 -9.5885 17 N5x N 16.6589 -8.2191 18 C8x C 15.2665 -8.0727 19 N1a N 19.3497 -9.6027 20 X F 16.9499 -13.7900 21 P1b P 7.2225 -10.2885 22 O1c O 5.8225 -10.2885 23 O1c O 7.2225 -8.8901 24 O1c O 7.2225 -11.6899BOND 26 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 1 5 1 6 1 6 1 #Down 7 2 7 1 #Up 8 8 9 1 9 9 10 1 10 3 10 1 #Up 11 5 11 1 #Up 12 11 12 1 13 8 13 2 14 13 14 1 15 14 15 2 16 15 16 1 17 9 16 2 18 16 17 1 19 17 18 2 20 18 10 1 21 15 19 1 22 13 20 1 23 12 21 1 24 21 22 1 25 21 23 2 26 21 24 1 |
